Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain Sells 23,172 Shares

Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain sold 23,172 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $1.16, for a total transaction of $26,879.52. Following the completion of the transaction, the chief executive officer now directly owns 120,293 shares of the company’s stock, valued at $139,539.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Gossamer Bio Trading Up 0.9 %

Shares of NASDAQ:GOSS traded up $0.01 on Thursday, hitting $1.18. 1,068,291 shares of the company’s stock were exchanged, compared to its average volume of 1,104,399. Gossamer Bio, Inc. has a 12 month low of $0.45 and a 12 month high of $1.88. The stock has a market capitalization of $266.18 million, a price-to-earnings ratio of -0.85 and a beta of 1.73. The business’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $0.91. The company has a debt-to-equity ratio of 3.14, a current ratio of 5.94 and a quick ratio of 5.94.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Analysts anticipate that Gossamer Bio, Inc. will post -0.72 EPS for the current fiscal year.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently made changes to their positions in GOSS. ARCH Venture Management LLC bought a new stake in shares of Gossamer Bio in the third quarter valued at about $6,709,000. Vanguard Group Inc. boosted its position in Gossamer Bio by 214.6% during the 3rd quarter. Vanguard Group Inc. now owns 11,268,328 shares of the company’s stock valued at $9,384,000 after acquiring an additional 7,686,213 shares in the last quarter. Silverarc Capital Management LLC purchased a new position in shares of Gossamer Bio in the 3rd quarter valued at $5,105,000. Monashee Investment Management LLC bought a new position in shares of Gossamer Bio in the 3rd quarter worth $4,417,000. Finally, Armistice Capital LLC bought a new stake in Gossamer Bio during the third quarter valued at about $4,127,000. 81.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $15.00 target price on shares of Gossamer Bio in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Wednesday, March 6th. Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective on shares of Gossamer Bio in a research note on Wednesday, March 6th. Finally, The Goldman Sachs Group dropped their price objective on shares of Gossamer Bio from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Gossamer Bio currently has an average rating of “Moderate Buy” and a consensus target price of $8.05.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.